Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956625 | 1.00 | DNMT1 (0.38) | DNMT1DNMT3ASMN1; SMN2HDAC1HDAC3 | |
| SCHEMBL5956640 | 0.88 | DNMT1 (0.34) | DNMT1DNMT3ASMN1; SMN2HDAC1HDAC3 | |
| SCHEMBL5956643 | 0.88 | DNMT1 (0.34) | DNMT1DNMT3ASMN1; SMN2HDAC1HDAC3 | |
| SCHEMBL5956589 | 0.83 | JAK2 (0.45) | DNMT1DNMT3ASMN1; SMN2SIRT5JAK2 | |
| SCHEMBL5956584 | 0.83 | JAK2 (0.45) | DNMT1DNMT3ASMN1; SMN2SIRT5JAK2 | |
| SCHEMBL5956725 | 0.79 | POLB (0.51) | DNMT1DNMT3ANPC1 | |
| SCHEMBL5956868 | 0.76 | KMT2A (0.47) | SIRT5KMT2AMEN1NPC1 | |
| SCHEMBL5956733 | 0.76 | KMT2A (0.47) | SIRT5KMT2AMEN1NPC1 | |
| SCHEMBL5956724 | 0.76 | KMT2A (0.47) | SIRT5KMT2AMEN1NPC1 | |
| Hydrochloric Acid SCHEMBL5956571 | 0.75 | KMT2A (0.47) | SIRT5KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | DNMT1 4188/4885DNMT3A 3905/4885SMN1; SMN2 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.